Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 14, 2007; 13(30): 4085-4090
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4085
Published online Aug 14, 2007. doi: 10.3748/wjg.v13.i30.4085
Table 1 Baseline characteristics of patients (mean ± SD)
All patients(n = 79) | Breakthrough(n = 24) | Non-breakthrough(n = 55) | |
Age (yr) | 47 ± 12 | 47 ± 13 | 47 ± 11 |
Female (%) | 32 | 29 | 33 |
Family history of CHB (%) | 47 | 46 | 55 |
ALT (IU/L) | 149 ± 44 | 98 ± 20 | 171 ± 63 |
Total bilirubin (mg/dL) | 1.1 ± 1.1 | 1.3 ± 1.4 | 1.0 ± 0.9 |
Albumin (g/dL) | 4.4 ± 0.4 | 4.2 ± 0.5 | 4.3 ± 0.4 |
(INR) | 1.07 ± 0.12 | 1.09 ± 0.15 | 1.06 ± 0.08 |
Cirrhosis (%) | 30 | 36 | 24 |
HBeAg-positive (%) | 43 | 56 | 36 |
HBV DNA log10 copies/mLa | 6.0 ± 1.6 | 6.6 ± 1.5 | 5.7 ± 1.5 |
Mean duration of lamivudine treatment (mo) | 26 ± 10 | 29 ± 11 | 25 ± 10 |
3 log < HBV DNA < 5 log (%) | 19 | 3 | 16 |
HBV DNA ≥ 5 log (%) | 60 | 21 | 39 |
- Citation: Chae HB, Hann HW. Baseline HBV DNA level is the most important factor associated with virologic breakthrough in chronic hepatitis B treated with lamivudine. World J Gastroenterol 2007; 13(30): 4085-4090
- URL: https://www.wjgnet.com/1007-9327/full/v13/i30/4085.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i30.4085